{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2022"],"submitter":["Wang Y"],"pubmed_abstract":["<h4>Introduction</h4>There has been controversy about renin-angiotensin system (RAS) inhibition in IgAN patients with advanced (stage 4) chronic kidney disease (CKD). Therefore, we investigated the effect of RAS blockade in these patients.<h4>Methods</h4>Renal specimens of 50 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2020, were stained using immunohistochemistry to detect the expression of RAS receptors (AT1R, AT2R, MasR, and MrgD). The primary endpoint was a composite of end-stage renal disease (ESRD) and death. Main baseline information and the administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) were collected.<h4>Results</h4>During a median follow-up time of 25.5 months, 21 (42.0%) patients reached "],"journal":["Journal of the renin-angiotensin-aldosterone system : JRAAS"],"pagination":["9162427"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9822756"],"repository":["biostudies-literature"],"pubmed_title":["IgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m<sup>2</sup> May Still Benefit from RAS Inhibition."],"pmcid":["PMC9822756"],"pubmed_authors":["Zhuo L","Li W","Jiang S","Wang Y","Zou G"],"additional_accession":[]},"is_claimable":false,"name":"IgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m<sup>2</sup> May Still Benefit from RAS Inhibition.","description":"<h4>Introduction</h4>There has been controversy about renin-angiotensin system (RAS) inhibition in IgAN patients with advanced (stage 4) chronic kidney disease (CKD). Therefore, we investigated the effect of RAS blockade in these patients.<h4>Methods</h4>Renal specimens of 50 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2020, were stained using immunohistochemistry to detect the expression of RAS receptors (AT1R, AT2R, MasR, and MrgD). The primary endpoint was a composite of end-stage renal disease (ESRD) and death. Main baseline information and the administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) were collected.<h4>Results</h4>During a median follow-up time of 25.5 months, 21 (42.0%) patients reached ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T11:10:50.969Z","creation":"2025-04-04T11:10:50.969Z"},"accession":"S-EPMC9822756","cross_references":{"pubmed":["36660420"],"doi":["10.1155/2022/9162427"]}}